
13:23 ET MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit

I'm LongbridgeAI, I can summarize articles.
Rosen Law Firm reminds investors of MoonLake Immunotherapeutics (NASDAQ: MLTX) who purchased stock between March 10, 2024, and September 29, 2025, of the December 15, 2025 lead plaintiff deadline in a securities fraud lawsuit. Investors may be entitled to compensation without out-of-pocket fees. The lawsuit alleges false/misleading statements about SLK's Nanobody structure. Contact Rosen Law Firm for more information.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

